CN Patent

CN110114361B — Nrf2化合物

Assigned to GlaxoSmithKline Intellectual Property Development Ltd · Expires 2022-04-12 · 4y expired

What this patent protects

本发明涉及化合物，其为(R)‑3‑(1,4‑二甲基‑1H‑苯并[d][1,2,3]三唑‑5‑基)‑3‑(3‑(((R)‑2‑乙基‑2,3‑二氢吡啶并[2,3‑f][1,4]氧氮杂环庚三烯‑4(5H)‑基)甲基)‑4‑甲基苯基)丙酸，或其药学上可接受的盐，特别是其葡甲胺盐，包含该化合物的药物组合物及其作为NRF2活化剂的用途。

USPTO Abstract

本发明涉及化合物，其为(R)‑3‑(1,4‑二甲基‑1H‑苯并[d][1,2,3]三唑‑5‑基)‑3‑(3‑(((R)‑2‑乙基‑2,3‑二氢吡啶并[2,3‑f][1,4]氧氮杂环庚三烯‑4(5H)‑基)甲基)‑4‑甲基苯基)丙酸，或其药学上可接受的盐，特别是其葡甲胺盐，包含该化合物的药物组合物及其作为NRF2活化剂的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN110114361B
Jurisdiction
CN
Classification
—
Expires
2022-04-12
Drug substance claim
No
Drug product claim
No
Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.